Network meta-analysis of eribulin versus other chemotherapies used as second- or later-line treatment in locally advanced or metastatic breast cancer
Abstract Background Eribulin mesylate (ERI; Halaven®) is a microtubule inhibitor approved in the United States for metastatic breast cancer patients with at least two prior chemotherapy regimens for metastatic breast cancer, and in the European Union in locally advanced breast cancer or metastatic b...
Main Authors: | Qi Zhao, Rachel Hughes, Binod Neupane, Kristin Mickle, Yun Su, Isabelle Chabot, Marissa Betts, Ananth Kadambi |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2021-06-01
|
Series: | BMC Cancer |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12885-021-08446-8 |
Similar Items
-
New opportunities to improve of duration and quality of life: eribulin in the treatment of patients with advanced breast cancer
by: T Yu Semiglazova, et al.
Published: (2016-06-01) -
Development of cytotoxic chemotherapy in metastatic breast cancer with a triple-negative phenotype
by: E V Karabina, et al.
Published: (2016-06-01) -
Combined use of apatinib mesylate and vinorelbine versus vinorelbine alone in recurrent or metastatic triple-negative breast cancer: study protocol for a randomized controlled clinical trial
by: Shuo Wu, et al.
Published: (2020-05-01) -
The results of the first retrospective data analysis of eribulin application in patients with metastatic breast cancer in actual clinical practice in Russia
by: L V Bolotina, et al.
Published: (2016-09-01) -
Clinical benefit of treatment with eribulin mesylate for metastatic triple‐negative breast cancer: Long‐term outcomes of patients treated in the US community oncology setting
by: Sarah S. Mougalian, et al.
Published: (2018-09-01)